The new, mobile positron emission tomography and computed tomography (PET-CT) systems will simplify treatment follow-up for many patients. The system has been completely redesigned to incorporate hardware improvements
The new Japanese trial is a 28 day, double-masked, dose-ranging study, in which approximately 120 Japanese patients with primary open-angle glaucoma or ocular hypertension, in one or both
BioFocus will apply Galapagos’s proprietary adenoviral platform to identify novel drug targets for the development of cancer therapies. The goal of the new collaboration will be to discover
Under the terms of the agreement, Crucell will continue to perform the development activities and will manufacture the final product. Crucell will receive a payment of E10 million
Under the terms of the agreement, Addex will receive $22 million upfront and is eligible for up to $455 million in research, development, regulatory and sales milestones for
Following a pre-IND meeting with the FDA, Innocoll will conduct two multi-centered Phase III clinical trials in the US to support the planned new drug application; the first
The Gore Vibrant study is a randomized, prospective, multi-center clinical trial intended to demonstrate patency superiority in the treatment of lesions eight centimetres or longer with the Gore
Canon Staar has been renamed Staar Japan and has become a wholly owned subsidiary of Staar operating directly in the Japanese market. The transaction is expected to increase
Assuming FDA acceptance of the IND application, Neopharm intends to enter a Phase I clinical study to assess the maximum tolerated dose and dose limiting toxicity (DLT) of
Under the terms of this agreement, which has a 10-year term, Biovail will manufacture and supply once-daily extended-release tramadol hydrochloride tablets in dosage strengths of 100mg, 200mg and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.